Biotech Drug Report Generated Jul 8, 2026

ABP 938

AMGN·AMGEN INC

NEUTRAL

Drug Impact Rating4/10

Trial Phase: Approved
Time to Market: Already marketed (launched October 2024)
Why 4/10: No upcoming binary catalyst, ABP 938 (Pavblu) was FDA-approved on August 23, 2024 and has been commercially marketed since October 2024. As an approved, marketed biosimilar at a mega-cap company (~$175B), there is no pending PDUFA, pivotal readout, or regulatory decision within ~12 months that could drive a significant share-price move. The defining binary already passed. ImpactScore 4 reflects an approved commercial product with no imminent hard catalyst.

Actionable Insight NEUTRAL

ABP 938/Pavblu is already approved and generating $700M/year in sales, the binary approval event is behind it. For Amgen investors, Pavblu is a meaningful contributor to the $3B biosimilar segment (37% YoY growth) but only ~2% of total $36.8B revenue. Watch for H2 2026 competition entry from other aflibercept biosimilars that could erode Pavblu's current monopoly pricing. The next significant Amgen catalysts are other pipeline readouts (e.g., IMDELLTRA, UPLIZNA), not this drug.

Price Chart

Loading chart...

Executive Summary

ABP 938 (branded Pavblu, generic aflibercept-ayyh) is Amgen's biosimilar to Regeneron's blockbuster eye drug Eylea (aflibercept). The FDA approved it on August 23, 2024 as the fifth aflibercept biosimilar, but Amgen was first to market with an at-risk launch in October 2024 after winning a patent battle with Regeneron. Pavblu generated a remarkable $700 million in its first full year (2025), Amgen's most successful biosimilar launch ever, and helped drive the company's biosimilar portfolio to $3 billion in sales (+37% YoY). However, Amgen's monopoly on the US aflibercept biosimilar market is expected to end in H2 2026 when competitors launch their versions. As an approved, marketed product at a $175B mega-cap company with no pending binary regulatory catalyst, the stock-moving binary event for this drug has already passed.

How It Works

ABP 938 is a biosimilar (a near-identical copy) of Eylea (aflibercept), a drug that blocks a protein called VEGF that causes abnormal blood vessel growth and leakage in the eye. It is injected directly into the eye to treat retinal diseases like wet age-related macular degeneration and diabetic eye disease.

Trial Status

Phase 3 trial (NCT04270747) completed, demonstrating no clinically meaningful differences from reference aflibercept (Eylea) in efficacy, safety, and immunogenicity in 566 patients with neovascular AMD. FDA approved August 23, 2024. Launched at-risk October 2024 after Federal Circuit denied Regeneron's injunction.

The Two-Sided Case

▲ Bull Case5

Pavblu was Amgen's most successful biosimilar launch ever, generating $700M in full-year 2025 sales, $258M in Q4 2025 alone, with 21% QoQ growth, according to Amgen's FY2025 earnings release and the BR&R analysis.

First-mover advantage: Pavblu was the first aflibercept biosimilar launched in the US (October 2024) and is expected to remain the only one on the market until at least H2 2026, giving Amgen ~2 years of monopoly pricing.

Amgen successfully navigated patent litigation, the Federal Circuit denied Regeneron's motion for a preliminary injunction, validating Amgen's at-risk launch strategy and removing near-term legal overhang.

Pavblu contributed to Amgen's $3B biosimilar portfolio (+37% YoY growth) and overall record revenue of $36.8B in 2025, demonstrating strong commercial execution.

Phase 3 data published in Ophthalmology Retina (August 2025) confirmed no clinically meaningful differences from reference Eylea in efficacy, safety, and immunogenicity, supporting sustained physician adoption.

▼ Bear Case5

Competition is coming: Other aflibercept biosimilars (Yesafili, Opuviz, Ahzantive, Enzeevu) are FDA-approved and expected to launch in H2 2026, which will likely trigger pricing erosion and market share loss for Pavblu.

Patent risk remains: Regeneron has signaled it is not done fighting, continued litigation or settlement terms could impact Pavblu's revenue trajectory over time.

Biosimilar pricing pressure is inherent to the category, as more competitors enter, ASPs typically decline 40-60% from reference brand levels, which will compress margins on Pavblu over time.

Pavblu's $700M in sales, while impressive, represents only ~2% of Amgen's $36.8B total revenue and ~0.4% of its ~$175B market cap, too small to be a needle-mover for the stock on its own.

Eylea franchise faces broader competitive threats from higher-dose Eylea HD, Vabysmo (Roche/Genentech), and emerging gene therapies (RGX-314) that could shrink the total addressable market for aflibercept biosimilars.

Upcoming Catalysts

H2 2026: Expected market entry of competing aflibercept biosimilars (Yesafili, Opuviz, Ahzantive, Enzeevu), which will end Pavblu's monopoly and pressure pricing.
Ongoing Regeneron patent litigation updates, any court ruling on remaining patent claims could affect Pavblu's long-term market access.
Quarterly earnings reports (Q1/Q2 2026) tracking Pavblu sales trajectory and market share as competition looms.

Source Filing

The SecBot filing or press-release report that triggered this drug report:

AMGEN INC COURT-RULING AMGN ·Originating report

Sources · 16

Hover a chip for the title

1 pubmed.ncbi.nlm.nih.gov2 ophthalmologytimes.com3 biologicshq.com4 centerforbiosimilars.com5 pearceip.law6 accessdata.fda.gov7 biosimilarsrr.com8 biosimilarsrr.com9 biologicshq.com10 insights.citeline.com11 amgen.com12 amgen.com13 biotechreality.com14 accessdata.fda.gov15 gabionline.net16 eureka.patsnap.com